A double-blind, comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric in-patients.
The efficacy and tolerability of the imidazopyridine hypnotic, zolpidem, were investigated in 119 elderly psychiatric in-patients complaining of insomnia in a double-blind, parallel-group, placebo-controlled trial. After a 7-day placebo washout period, patients were randomized to receive 10 or 20 mg/day zolpidem, or placebo for 21 days; thereafter, all patients received placebo for 7 days. Sleep was assessed by patient observation on days 0, 1, 7, 14, 21, 22 and 28. Compared with placebo, 20 mg/day zolpidem significantly improved total duration of sleep between day 0 and day 21, and this was maintained at day 28. After 10 or 20 mg/day zolpidem, there was also a trend towards improvement in all other sleep parameters, which remained above baseline at day 28. Zolpidem was well tolerated with no withdrawal symptoms during the second 7-day placebo treatment period. Daytime drowsiness was reported in three patients receiving 20 mg/day zolpidem and in one receiving 10 mg/day zolpidem, but there was no significant increase in daytime drowsiness between days 0 and 21. Ataxia occurred in two, one and one patient, respectively, treated with 20 mg/day zolpidem, 10 mg/day zolpidem and placebo. The incidences of other adverse events or effects on clinical and laboratory parameters were minimal and similar in all three treatment groups. It is concluded that, in elderly psychiatric patients, 10 mg/day zolpidem can be used to treat insomnia and can be safely added to concomitant psychotropic treatment without inducing daytime drowsiness.
Shaw
S H
SH
Department of Psychiatry, Stanley Royd Hospital, Wakefield, UK.
Curson
H
H
Coquelin
J P
JP
D000368:Aged; D003704:Dementia / Q000150:complications; D003863:Depression / Q000150:complications; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use*; D007297:Inpatients; D008297:Male; D010919:Placebos; D011618:Psychotic Disorders / Q000150:complications; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D012559:Schizophrenia / Q000150:complications; D012890:Sleep / Q000187:drug effects; D007319:Sleep Initiation and Maintenance Disorders / Q000150:complications / Q000188:drug therapy*; D011795:Surveys and Questionnaires; D000077334:Zolpidem
D006993:Hypnotics and Sedatives; D010919:Placebos; D011725:Pyridines; D000077334:Zolpidem